👩‍🏫 Professional Activities
I facilitate enablement programs so R&D, clinical, and data teams can run complex bioinformatics workflows with confidence.
Below is a snapshot of my interested fields and topics across recent roles.
Precision Scientific · 2021–2024
R&D | Middle bioinformatics engineer
Cancer auxiliary diagnosis enablement
2022-2024
- MRD
- HRD
- WGD
- ML
- Pipeline
- Analytics
- Designed and productionized circulating tumor DNA–based Minimal Residule Diesase (MRD) pipelines (study design → feature engineering → data analysis → statistical reporting).
- Delivered 4 clinical MRD studies and translated results into regulatory-ready reports; one outcome presented at SGO 2024; co-authored 2 manuscripts (one published).
- Analyzed whole-genome doubling (WGD) using low-pass whole genome sequencing (WGS) in ~1Ă— coverage; standardized WGD definitions across four studies.
- Built machine learning classifiers using platelet RNA-seq data to differentiate uterine sarcoma vs. leiomyoma; conducted end-to-end analysis workflow (RNA-seq preprocessing → feature engineering → model evaluation → biomarker detection).
- Contributed to the national HRD reference standard project led by China’s National Institutes for Food and Drug Control.
Cell & gene therapy bioinformatics
2023-2024
- Cell therapy
- AAV
- Off-target
- CRISPR
- Built analysis workflows for viral integration site mapping, AAV mutation detection, and CRISPR off-target assessments.
- Support product development and clinical trials for 5 cell & gene therapy products.
Bioinformatics workflow automation
2021-2022
- WDL/Cromwell
- Cloud computing
- Workflow automation
- Designed and productionized an integrated bioinformatics pipeline for cancer genomics using the Workflow Description Language (WDL) and Cromwell; automated data processing and analysis workflows on the cloud (Alibaba Cloud).
- Developed seperated WDL modules for each step of the pipeline in a high flexible framework, testified and validated the consistency of the pipeline outputs.
- Reduced the pipeline runtime by 50% and cost by 50%.
GrandOmics Biosciences · 2019–2021
R&D | Middle bioinformatics engineer
Rare disease diagnosis
2019–2021
- TGS
- DMD
- SNV/InDel
- SV
- Led development of China’s first targeted capture panel for third-generation sequencing for Duchenne muscular dystrophy (DMD).
- Achieved improved sensitivity and accuracy for SV, SNV, and InDel detection compared to gold-standard approaches.
- Realized workflow automation, conducted 4 studies, and published 2 papers.
Pathogen surveillance and diagnosis
2020-2021
- COVID-19
- Pathogen
- Galaxy
- Epidemiology
- Built a Galaxy-based pathogen surveillance system during COVID-19 for mutation tracking, lineage analysis, and visualization
- Designed targeted amplification kits covering 30 respiratory pathogens.
- Implemented end-to-end pipelines for identification, automated reporting, and interactive dashboards.
- Delivered analysis tools accessible to wet-lab and clinical users.
Sequencing technology benchmarking
2019-2020
- Nanopore
- PacBio
- Illumina
- Galaxy
- Conducted systematic benchmarking of basecalling and variant accuracy across sequencing platforms
- Compared Nanopore R9 vs. R10 chemistry performance
- Evaluated Nanopore vs. PacBio vs. Illumina for SNV, InDel, and structural variant detection
Geneis Beijing · 2017–2019
R&D | Bioinformatics engineer
Oncology Assay & Biomarker Panel Development
2018–2019
- Targeted sequencing
- CNV
- MSI
- Clinical diagnostics
- Developed targeted amplification panel for lung cancer biomarkers; established CNV baseline thresholds using MAD-based normalization.
- Implemented MSI profiling and visualization for genomic instability assessment
- Delivered reproducible analysis workflows for clinical reporting.
Multi-omics Analysis in Developmental Biology
2017–2018
- RNA-seq
- Methylation
- Pathway
- Performed differential expression and methylation analysis of mouse oocytes (in vitro vs. in vivo; GV vs. MII); identified key transcription factors and maturation-associated pathways
- Integrated transcriptomic and epigenomic signals to characterize developmental regulation.
- Generated interpretable visualizations and biological summaries for collaborators.
Clinical Cancer Genomics & Survival Analysis
2017–2018
- Targeted sequencing
- SNV/InDel
- MSI
- TMB
- Conducted retrospective gastric cancer genomics analysis across SNV, InDel, CNV, MSI, and TMB.
- Evaluated clinical correlations and survival outcomes using Kaplan–Meier analysis.
- Supported biomarker interpretation for translational research studies.